Byword Medical Marketing

05/04/2021

test

05/04/2021

test

19/06/2017

Stent Grafts Market Research Report

Global Stent Grafts Market 2017-2022: Global Stent Grafts market Report offers decisive insights into the overall Stent Grafts industry along with the market dimensions and evaluation for the duration 2017 to 2022. The forenamed research study covers extensive analysis of various Stent Grafts indust...

19/06/2017

DUBLIN and VIENNA- Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive ATP(TM) therapy slows the progression of AF in patients with implanted cardiac devices. A robust, real-world analysis of ne...

19/06/2017

“He was a pretty awesome mentor,” said Medtronic manager Craig Schmidt

Paul Skarstad was a pioneering scientist at Medtronic who helped shrink the size of pacemakers and other medical devices by designing smaller, more powerful batteries that last much longer than their predecessors. As a result of Skarstad’s groundbreaking research, the devices are now more reliable a...

19/06/2017

What has prompted Boston Scientific to look towards endoscopy as a growth driver? Read this to find out.

We estimate that endoscopy constitutes around 20% of Boston Scientific‘s value. The company has made a number of acquisitions to strengthen its endoscopic product portfolio in recent years. So why is it doing so? The medical devices market has become incredibly competitive, and mergers and acquisiti...

09/06/2017

We can't further emphasise how important an online presence is. How's yours? Comic Source: getelastic

08/06/2017

Boston Scientific’s next-generation Vercise Gevia Deep Brain Stimulation System incorporates new programming software that enables physicians to see how stimulation will be distributed in the brain while they are personalizing therapy.

Boston Scientific picked up a CE mark for its rechargeable, MRI-compatible deep-brain stimulation (DBS) system for the treatment of movement disorder symptoms in Parkinson’s disease, dystonia and essential tremor. While all three conditions are currently incurable, DBS is used to alleviate symptoms....

08/06/2017

This also marks the 20th anniversary of Boston Scientific’s European Innovation Centre in Galway, which has produced more than three million devices in total.

Boston Scientific’s announcement that it is to invest €17 million in its new Endoscopy design facility in Galway, “reaffirms Ireland’s position as one of the international leaders in the medtech industry”. This is the view of the Minister for Gaeltacht Affairs and Natural Resources and Fine Gael Gal...

08/06/2017

More about Edwards Lifesciences: Like our page for news updates!

Medical equipment major Edwards Lifesciences Corporation EW recently announced the receipt of FDA approval for aortic and mitral valve-in-valve procedures using SAPIEN 3 transcatheter heart valve (THV). This expanded indication represents the first appr oval for the SAPIEN 3 valve in the U.S. for bi...

06/06/2017

ISPE awards company for a Flexible Filling Line that can process different containers on the same pharmaceutical line.

Cook Pharmica won the ISPE “Facility of the Year Award” (FOYA) for the “Flexible Filling Line” (FFL). The project was executed together with Optima Pharma as a partner for filling, closing and isolator technologies. The FFL consists of the OPTIMA MultiUse Filler, which was designed and developed esp...

06/06/2017

This diagram shows the position of Abbott Laboratories in various areas of the cardiovascular segment after its complete integration of St. Jude Medical.

On January 4, 2017, Abbott Laboratories (ABT) announced the completion of its acquisition of St. Jude Medical. The deal is expected to catapult Abbott to a dominant position in all areas of the cardiovascular device market, currently valued at ~$30 billion. St. Jude Medical has added a strong portfo...

06/06/2017

Saluda is developing an implantable medical device to treat chronic back pain and other conditions using electrical pulses.

Medtronic has joined in a $40 million round of equity financing for Saluda Medical, a med-tech company with operations in the Twin Cities. Saluda is developing an implantable medical device to treat chronic back pain and other conditions using electrical pulses. The Australia-based company expanded…

06/06/2017

This anticipated FDA approval of the indication expansion was supported by real-world data collected from the STS/ACC TVT Registry.

IRVINE, Calif., June 5, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has received U.S. Food and Drug Administration (FDA) approval for aortic and mitral…

06/06/2017

About Surgical solutions, Patient monitoring and Recovery, and Surgical Technologies

The Surgical and Patient Monitoring business has been a cornerstone of Medtronic‘s growth. The company has grown both organically and inorganically in this market. We estimate that this business constitutes nearly 40% of Medtronic’s value, with nearly $11.5 billion in annual revenue and close to $8…

23/05/2017

"The Edwards' CENTERA valve is repositionable and retrievable and can be delivered through a low-profile 14-French delivery system that features a motorized handle that results in stable valve deployment. The valve is uniquely packaged – fully pre-attached which facilitates simple and rapid device preparation."

PARIS, May 17, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced late-breaking data at EuroPCR 2017 demonstrating excellent clinical outcomes for transcatheter a...

23/05/2017

Read on for favorable one-year outcomes from the largest study of real-world experience for Abbott's MitraClip system in transcatheter mitral valve repair (TMVR) procedures.

– 92.8% procedural success observed in reducing leaky heart valve – 80.0% of those treated free from repeat heart failure re-hospitalization – 85.9% of patients were discharged to home after two-day average hospital stay WASHINGTON, March 18, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced fa...

23/05/2017

More good news from Boston Scientific: The WATCHMAN's impressively low ischemic stroke rate favors left atrial appendage closure as an important therapy for patients ineligible for long-term oral anticoagulation.

Largest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017 MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from th...